“Reimagining what life with schizophrenia could look like”

Schizophrenia may be one of the most widely mischaracterized conditions in psychiatry. It’s often portrayed in extreme or oversimplified ways in popular media, which can create the impression that everyone experiences the condition the same way. In reality, schizophrenia exists on a spectrum; no two people experience it identically.

For most people, it’s also difficult to interpret what’s happening biologically when someone has symptoms like hallucinations, delusions or disorganized thinking. Without that understanding, stigma can fill the gap.

That confusion is compounded by when the disease tends to strike. Schizophrenia often emerges during late adolescence or early adulthood, a period when the last thing a young person expects is a serious brain disorder. By the time they’re facing the reality of their symptoms, the stigma is already working against them. The misconception that people with schizophrenia can’t function or work can delay diagnosis and appropriate care at exactly the moment when early intervention matters most.

I saw this firsthand as a practicing psychiatrist. I worked with many young people whose first psychotic episodes completely disrupted their lives and their families’ sense of stability. The level of suffering and the ripple effect on families cannot be overstated. That’s what drives my commitment to pushing treatment forward.

The primary challenge is the complexity of the disease itself. Its symptoms and progression can vary widely based on biological, psychological and social factors, which makes it difficult for even experienced clinicians to navigate. Historically, one of the biggest hurdles has been how long it can take to confirm a diagnosis. Because clinical manifestation and progression of symptoms is variable, it’s not easy to confirm a diagnosis of schizophrenia in a single medical encounter or visit. That can take years—time during which the disease may continue to progress.

Early diagnosis and intervention are absolutely crucial. We know that the first few years after symptom onset are a particularly vulnerable period, when untreated psychosis can lead to worsening cognitive and functional outcomes, such as severe lack of motivation, challenges with self-care and social withdrawal. These outcomes only make it harder to reach—and help—some patients.

Medication adherence is another significant challenge. Estimates suggest that 40 to 55% of people with schizophrenia struggle to stay on their prescribed treatment. But this isn’t simply about forgetting to take medication. Cognitive symptoms and altered perceptions of reality can make it difficult for patients to understand why they need treatment in the first place.

That’s one of the reasons LAIs have been meaningful for this patient population. These medications are given at regular intervals and can help support continuity of care. Since LAIs are a professionally administered medication, treatment teams know when a patient has missed a dose and can intervene.

But medication alone is never enough.

A truly comprehensive treatment approach must also include psychosocial support—such as counseling, peer support, social services and vocational programs—to help people rebuild skills, confidence and quality of life.

In schizophrenia, a relapse isn’t just a return of symptoms; it can alter the long-term course of the disease. Schizophrenia often involves what we call “positive symptoms,” such as hallucinations or delusions, and “negative symptoms,” including loss of motivation, diminished emotional expression or withdrawal from social interaction.

What makes relapse particularly serious is its cumulative effect on the brain. Each episode can reduce the brain’s ability to recover, making future relapses more likely and worsening the patient’s long-term outcomes. We see this translate into a decline in functional recovery (the ability to work or study) and social recovery (the ability to connect with others).

The numbers reflect how common this is: Nearly eight in 10 patients experience a relapse within five years of their first episode. On average, an adult with schizophrenia experiences nine relapses in less than six years. That’s why the first three to five years of care are so critical, and why reducing the risk of relapse has become a primary treatment goal.

I think the company’s legacy in treating mental illnesses has been foundational in this field, particularly the revolutionary work in schizophrenia in the 1950s when Dr. Paul Janssen discovered one of the first medicines to effectively treat the core symptoms of the disease. At a time when care was largely limited to institutional settings, this breakthrough helped shift the treatment paradigm in schizophrenia by allowing many people to be treated at home for the first time.

While these early dopamine‑blocking therapies were transformative, they often came with significant side effects.

Over time, continued innovation led to treatments that put patients at the center, with improved tolerability, followed by the introduction of LAIs, which enabled the potential for long‑term stability and a reduction in the risk of relapse.

Today, we recognize that no single approach works for everyone. Some patients benefit from the consistency of LAIs, while others may prefer oral therapies. By offering a broad range of options, we aim to empower healthcare providers to tailor treatment plans based on each person’s unique clinical needs, circumstances and goals. This approach continues a commitment that began with reimagining what life with schizophrenia could look like.